Petvivo Holdings Stock Price, News & Analysis

PetVivo Holdings reported substantial growth in the second quarter of fiscal 2023. Revenues surged to $223,280, a significant increase from $4,977 year-over-year, primarily driven by sales of their Spryng™ product to MWI Animal Health. Operating expenses rose to $2,194,689 due to costs associated with product launch and public company expenses, leading to an operating loss of $2,119,568. The net loss was $2,111,589, or ($0.21) per share. As of September 30, 2022, the company had $2.3 million in cash and $2.1 million in working capital.

PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) announced its participation in the American Association of Equine Practitioners (AAEP) conference from November 19-22, 2022, in San Antonio, Texas. The company will showcase its lead product, SPRYNG™ with OsteoCushion™ Technology, designed for treating lameness and joint issues like osteoarthritis in animals. CEO John Lai emphasized the importance of networking to advance their veterinary medical device. Additionally, Dr. Joseph Manning will present on the product during the conference, further enhancing the company's visibility within the veterinary community.

PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) will release its financial results on November 10, 2022, after market close and host a conference call at 4:00 p.m. CT (5:00 p.m. ET) to discuss these results. The live webcast can be accessed through PetVivo's Investor Relations website.

The company focuses on innovative medical therapeutics for animals, with a pipeline of 17 products and 19 patents, including its lead product, SPRYNG™, designed for joint-related afflictions in dogs and horses.

PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) will present at the 15th annual LD Micro Main Event on October 26, 2022, from 08:00 AM to 8:25 AM PT at the Luxe Sunset Boulevard Hotel. CEO John Lai plans to highlight the company's innovative veterinary medical device, SPRYNG, aimed at managing osteoarthritis in animals. The event, running from October 25-27, features over 200 companies. PetVivo has a pipeline of products and holds nineteen patents, ensuring its commitment to developing effective therapies for companion animals.

PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) announced that its product, Spryng™ with OsteoCushion™ Technology, is now available for purchase through MWI Animal Health. Under an exclusive distribution agreement, MWI will market and promote Spryng to veterinarians across the U.S., expanding its presence in the animal health market. Spryng is designed to treat joint afflictions like osteoarthritis in equine and companion animals. The partnership aims to provide veterinarians with innovative tools for managing lameness, benefiting both animals and their owners.

PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) has appointed Paula Wittler as the new Business Development Manager for the Western Region. Wittler brings over 25 years of experience in veterinary product management and marketing, previously working with Zoetis Animal Health. CEO John Lai emphasized her role in promoting Spryng™, a veterinary medical device designed to improve the treatment of lameness and joint issues in companion animals. PetVivo continues to focus on innovative biomedical devices and has a robust product pipeline, furthering its mission in animal health.

PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) will present at the H.C. Wainwright Global Investment Conference from September 12-14, 2022, in New York. CEO John Lai has recorded an overview of the company's business for this event. PetVivo is focused on developing and commercializing innovative medical devices for pets, with a portfolio of 17 products and 19 patents. Its lead product, SPRYNG™ with OsteoCushion™ technology, is available for managing joint-related afflictions in animals.

PetVivo Holdings, Inc. (Nasdaq: PETV) reported its first quarter fiscal 2023 financial results, showing a revenue increase to $58,174 from $4,145 in Q1 2022, driven by the commercialization of its Spryng™ device. Despite the revenue growth, the company faced a quarterly operating loss of $1,966,093 compared to $518,519 in the previous year, primarily due to increased costs associated with Spryng™ and other public company expenses. The net loss was $1,965,428, or ($0.20) per share. Cash and working capital stood at $4.4 million and $3.8 million, respectively.

PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) has announced the appointment of Rob Costantino and Leslie Coolidge to its Board of Directors. Mr. Costantino brings extensive financial and operational expertise from his prior roles as CEO and CFO at major corporations, including a pivotal turnaround at Mitsubishi Motors Credit. Ms. Coolidge, a former audit partner at KPMG, has significant experience in public company financial reporting. Both appointments are expected to enhance company strategy and governance, positioning PetVivo for growth in the innovative biomedical sector for companion animals.